[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100511752":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":31,"responsibleParty":153,"collaborators":10,"id":155,"slug":156,"hasResults":157,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":10,"eligibilityCriteria":161,"healthyVolunteers":157,"sex":162,"minAge":163,"maxAge":164,"enrollmentInfo":165,"targetDuration":10,"studyType":168,"phases":10,"briefSummary":169,"conditions":170,"keywords":172,"overallStatus":34,"whyStopped":10,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":183},{"fullName":5,"class":6},"Novartis","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Asciminib",null,"Patients prescribed with Asciminib at physicians' discretion as per locally approved label under usual clinical practice",[13],"Other: Asciminib",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"OTHER","There is no treatment allocation. Asciminib will be prescribed by the physician as per locally approved label. No drug will be dispensed from Novartis",[9],[20],"Scemblix",[22],{"name":23,"affiliation":23,"role":24},"Novartis Pharmaceuticals","STUDY_DIRECTOR",[26,30],{"name":23,"role":27,"phone":28,"phoneExt":10,"email":29},"CONTACT","+41613241111","novartis.email@novartis.com",{"name":23,"role":27,"phone":10,"phoneExt":10,"email":10},[32,45,54,62,70,78,86,94,99,104,110,119,122,130,135,140,145],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":10,"cosmosGeoPoint":39,"geoPoint":44,"contacts":10},"Novartis Investigative Site","RECRUITING","Wŏnju","Gangwon-do","26426","South Korea",{"type":40,"coordinates":41},"Point",[42,43],127.94528,37.35139,{"lat":43,"lon":42},{"facility":33,"status":34,"city":46,"state":47,"zip":48,"country":38,"countryCode":10,"cosmosGeoPoint":49,"geoPoint":53,"contacts":10},"Anyang-si","Gyeonggi-do","14068",{"type":40,"coordinates":50},[51,52],126.92694,37.3925,{"lat":52,"lon":51},{"facility":33,"status":34,"city":55,"state":47,"zip":56,"country":38,"countryCode":10,"cosmosGeoPoint":57,"geoPoint":61,"contacts":10},"Bucheon-si","14584",{"type":40,"coordinates":58},[59,60],126.78306,37.49889,{"lat":60,"lon":59},{"facility":33,"status":34,"city":63,"state":47,"zip":64,"country":38,"countryCode":10,"cosmosGeoPoint":65,"geoPoint":69,"contacts":10},"Uijeongbu-si","11759",{"type":40,"coordinates":66},[67,68],127.0474,37.7415,{"lat":68,"lon":67},{"facility":33,"status":34,"city":47,"state":71,"zip":72,"country":38,"countryCode":10,"cosmosGeoPoint":73,"geoPoint":77,"contacts":10},"Korea","10408",{"type":40,"coordinates":74},[75,76],126.76917,37.58944,{"lat":76,"lon":75},{"facility":33,"status":34,"city":79,"state":71,"zip":80,"country":38,"countryCode":10,"cosmosGeoPoint":81,"geoPoint":85,"contacts":10},"Incheon","405 760",{"type":40,"coordinates":82},[83,84],126.70515,37.45646,{"lat":84,"lon":83},{"facility":33,"status":34,"city":87,"state":71,"zip":88,"country":38,"countryCode":10,"cosmosGeoPoint":89,"geoPoint":93,"contacts":10},"Seoul","02841",{"type":40,"coordinates":90},[91,92],126.9784,37.566,{"lat":92,"lon":91},{"facility":33,"status":34,"city":87,"state":87,"zip":95,"country":38,"countryCode":10,"cosmosGeoPoint":96,"geoPoint":98,"contacts":10},"03080",{"type":40,"coordinates":97},[91,92],{"lat":92,"lon":91},{"facility":33,"status":34,"city":87,"state":87,"zip":100,"country":38,"countryCode":10,"cosmosGeoPoint":101,"geoPoint":103,"contacts":10},"06351",{"type":40,"coordinates":102},[91,92],{"lat":92,"lon":91},{"facility":33,"status":34,"city":87,"state":105,"zip":106,"country":38,"countryCode":10,"cosmosGeoPoint":107,"geoPoint":109,"contacts":10},"Yangcheon gu","07985",{"type":40,"coordinates":108},[91,92],{"lat":92,"lon":91},{"facility":33,"status":34,"city":111,"state":112,"zip":113,"country":38,"countryCode":10,"cosmosGeoPoint":114,"geoPoint":118,"contacts":10},"Suwon","Yeongtong Gu","16499",{"type":40,"coordinates":115},[116,117],127.00889,37.29111,{"lat":117,"lon":116},{"facility":33,"status":34,"city":120,"state":10,"zip":121,"country":38,"countryCode":10,"cosmosGeoPoint":10,"geoPoint":10,"contacts":10},"Jeollanam","519763",{"facility":33,"status":34,"city":123,"state":10,"zip":124,"country":38,"countryCode":10,"cosmosGeoPoint":125,"geoPoint":129,"contacts":10},"Pusan","614 735",{"type":40,"coordinates":126},[127,128],128.02524,35.70128,{"lat":128,"lon":127},{"facility":33,"status":34,"city":87,"state":10,"zip":131,"country":38,"countryCode":10,"cosmosGeoPoint":132,"geoPoint":134,"contacts":10},"03722",{"type":40,"coordinates":133},[91,92],{"lat":92,"lon":91},{"facility":33,"status":34,"city":87,"state":10,"zip":136,"country":38,"countryCode":10,"cosmosGeoPoint":137,"geoPoint":139,"contacts":10},"05505",{"type":40,"coordinates":138},[91,92],{"lat":92,"lon":91},{"facility":33,"status":34,"city":87,"state":10,"zip":141,"country":38,"countryCode":10,"cosmosGeoPoint":142,"geoPoint":144,"contacts":10},"06591",{"type":40,"coordinates":143},[91,92],{"lat":92,"lon":91},{"facility":33,"status":34,"city":146,"state":10,"zip":147,"country":38,"countryCode":10,"cosmosGeoPoint":148,"geoPoint":152,"contacts":10},"Taegu","41944",{"type":40,"coordinates":149},[150,151],128.07278,34.88889,{"lat":151,"lon":150},{"type":154,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100511752","asciminib-rmp-study-100511752",false,"NCT05943522","Asciminib RMP Study","A Post Approval Surveillance of Scemblix® (Asciminib) in Patients With Chronic Myeloid Leukemia (CML) in Korea","Inclusion criteria\n\n1. Adult patients diagnosed with Ph+ CP-CML and currently receiving or going to receive Scemblix® treatment according to locally approval label\n2. Patients who are willing to provide written informed consent prior to study enrollment\n\nExclusion criteria\n\n1. Patients with contraindication according to locally approved label of Scemblix®\n2. Patients who receive or are going to receive any investigational medicine during the observation period","ALL","18 Years","100 Years",{"count":166,"type":167},600,"ESTIMATED","OBSERVATIONAL","This study is a prospective, open-label, multi-center, non-comparative, observational study to assess safety and effectiveness of Asciminib in the real-world clinical setting in Korean Chronic myeloid leukemia (CML) patients.",[171],"Chronic Myeloid Leukemia",[20,9,173,171],"CML","2026-04-17",{"date":176,"type":177},"2026-04-20","ACTUAL",{"date":179,"type":177},"2023-07-19",{"date":181,"type":167},"2030-06-07",{"name":23,"class":6},17]